Topical Calcineurin Inhibitors
On this page
Direct answer
Topical calcineurin inhibitors are non-steroidal immunomodulators, chiefly tacrolimus and pimecrolimus, that block calcineurin in T cells and reduce cytokine transcription without causing skin atrophy. They are used for atopic dermatitis on the face, neck and skin folds, where steroids are undesirable, and as steroid-sparing therapy in vitiligo. Early burning and itching are common adverse effects, and a boxed warning covers malignancy and serious infection.
What you must remember
- Mechanism: tacrolimus binds FKBP-12 and pimecrolimus binds macrophilin-12, and each complex inhibits calcineurin, blocking nuclear factor of activated T cells.
- Strengths: tacrolimus ointment 0.03 percent for children and 0.1 percent for adults, and pimecrolimus cream 1 percent.
- Indications: moderate atopic dermatitis of the face, neck and flexures, and vitiligo, the latter often off-label.
- No atrophy: the drugs do not thin the skin, which is the main reason they suit the face and folds.
- Early burning: stinging and itching at application are common early effects and often lessen with continued use.
- Boxed warning: a possible risk of malignancy, including lymphoma, and of serious infection, which restricts use to second-line therapy.
- Infection caution: herpes simplex infections, including eczema herpeticum, need careful review, since the drug impairs local immunity.
Choosing between tacrolimus and pimecrolimus
The two agents share a mechanism but differ in potency and licensed strength, which matters for prescribing. The table sets out the differences that are most often tested.
| Feature | Tacrolimus | Pimecrolimus |
|---|---|---|
| Strengths | 0.03 and 0.1 percent ointment | 1 percent cream |
| Relative potency | Higher | Lower |
| Usual setting | Moderate to severe atopic dermatitis, vitiligo | Mild to moderate atopic dermatitis |
| Boxed warning | Yes | Yes |
| Commonly used from | 2 years of age | 2 years of age |
Tacrolimus is the stronger choice for severe or resistant disease, while pimecrolimus suits milder cases and sensitive skin. Both carry the same boxed warning, so duration and intermittent use matter more than the choice of agent. Age limits in the product label should be followed, since use under 2 years is off-label in many markets.
In practice, the drug is usually applied once or twice daily until the lesions settle, followed by intermittent maintenance on the sites that flare. Patients should be told that the drug is not a steroid and does not thin the skin, which improves adherence on the face.
Where the exam tries to catch you
Calcineurin inhibitor questions mostly test the mechanism, the safety warning and the absence of atrophy.
- Trap: assuming calcineurin inhibitors thin the skin like steroids Correct: they do not cause atrophy, which is why they suit the face, neck and flexures.
- Trap: ignoring the boxed warning because the drug is non-steroidal Correct: the warning covers malignancy and serious infection, so use is limited to second-line and intermittent maintenance.
- Trap: stopping treatment for early burning Correct: early burning is common and often eases with continued use, so patients are counselled before treatment is stopped.
Frequently asked questions
What is the mechanism of tacrolimus in atopic dermatitis?
Tacrolimus binds the intracellular protein FKBP-12, and the complex inhibits calcineurin. This blocks nuclear factor of activated T cells, reducing transcription of interleukin-2 and other inflammatory cytokines. Tacrolimus therefore calms eczema without the atrophy caused by corticosteroids.
Why do topical calcineurin inhibitors carry a boxed warning?
Topical calcineurin inhibitors carry a boxed warning for a possible risk of malignancy, including lymphoma, and for serious infections. The concern comes from experience with systemic immunosuppressants, so the warning is applied to topical use as a precaution. Use is therefore limited to second-line or intermittent treatment where possible.
Which strengths of tacrolimus ointment are used in atopic dermatitis?
Tacrolimus ointment is available as 0.03 percent and 0.1 percent. The 0.03 percent strength is usually used for children, and the 0.1 percent strength for adults with moderate to severe disease. Pimecrolimus is supplied as a 1 percent cream.
Are topical calcineurin inhibitors used in vitiligo?
Topical tacrolimus is used in vitiligo as a steroid-sparing option, particularly on the face and neck where atrophy matters. Benefit is often gradual, and sun protection is advised during treatment. Use in vitiligo is commonly off-label, so specialist practice guides it.